Sep 12, 2022 / 11:00AM GMT
Lee Chan - H.C. Wainwright & Co., LLC - Analyst
Thank you for joining the H.C. Wainwright 24th Annual Global Investment Conference. My name is Lee Chan, and I'm a healthcare analyst at H.C. Wainwright. Today, we have Mr. James McCullough, CEO of Renalytix join us for fireside chat. Welcome, James.
James McCullough - Renalytix PLC - CEO
Good afternoon. I'm delighted to be here.
Questions and Answers:
Lee Chan - H.C. Wainwright & Co., LLC - AnalystSo Renalytix markets the KidneyIntelX test for prognosis of kidney [accounts]. Could you tell us what the test measures and how physicians can use that [test result]?
James McCullough - Renalytix PLC - CEO
Yeah. So KidneyIntelX is really a program where -- which is based on an in vitro diagnostic. So we take a blood drop. And we measure three circulating proteins, which have a long history in the literature of understanding kidney disease progression. And to that, we add a whole sequence of features from a patient's